In a filing, Day One Biopharmaceuticals Inc revealed its HEAD OF R&D Blackman Samuel C. unloaded Company’s shares for reported $0.4 million on Dec 10 ’24. In the deal valued at $13.31 per share,30,000 shares were sold. As a result of this transaction, Blackman Samuel C. now holds 1,034,015 shares worth roughly $13.07 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, Bender Jeremy sold 10,554 shares, generating $139,420 in total proceeds. Upon selling the shares at $13.21, the CHIEF EXECUTIVE OFFICER now owns 108,377 shares.
Before that, Blackman Samuel C. sold 2,206 shares. Day One Biopharmaceuticals Inc shares valued at $29,142 were divested by the HEAD OF R&D at a price of $13.21 per share. As a result of the transaction, Blackman Samuel C. now holds 1,064,015 shares, worth roughly $13.45 million.
Needham reiterated its Day One Biopharmaceuticals Inc [DAWN] rating to a Buy in a research note published on October 09, 2024; the price target was $33. A number of analysts have revised their coverage, including BofA Securities’s analysts, who increased its forecast for the stock in early August from “an Underperform” to “a Buy”. Needham also remained covering DAWN and reiterated its “Buy” recommendation on April 24, 2024. BofA Securities revised its rating on April 25, 2023. It rated DAWN as “an Underperform” which previously was an “a Buy”.
Price Performance Review of DAWN
On Tuesday, Day One Biopharmaceuticals Inc [NASDAQ:DAWN] saw its stock jump 0.16% to $12.64. Over the last five days, the stock has lost -4.39%. Day One Biopharmaceuticals Inc shares have fallen nearly -13.42% since the year began. Nevertheless, the stocks have fallen -11.36% over the past one year. While a 52-week high of $18.07 was reached on 05/01/24, a 52-week low of $11.94 was recorded on 06/17/24. SMA at 50 days reached $14.15, while 200 days put it at $14.42.
Levels Of Support And Resistance For DAWN Stock
The 24-hour chart illustrates a support level at 12.45, which if violated will result in even more drops to 12.27. On the upside, there is a resistance level at 12.79. A further resistance level may holdings at 12.95. The Relative Strength Index (RSI) on the 14-day chart is 34.92, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.67, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 89.22%. Stochastics %K at 12.25% indicates the stock is a buying.
How much short interest is there in Day One Biopharmaceuticals Inc?
A steep rise in short interest was recorded in Day One Biopharmaceuticals Inc stocks on 2024-11-29, growing by 1.47 million shares to a total of 19.49 million shares. Yahoo Finance data shows the prior-month short interest on 2024-10-31 was 18.02 million shares. There was a rise of 7.53%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on February 08, 2023 when CapitalOne began covering the stock and recommended ‘”an Overweight”‘ rating along with a $40 price target.
